Pluristem Therapeutics Inc (PSTI)

[FDApproved]

Note...The Reserved Presentations, Some Company(s) Wants It Quiet Until Next Tuesday Morning.


http://www.worldstemcellsummit.com/sessions/engineering-next-frontier-cellular-immunotherapy-looking-beyond-cd19/


Material Threat MCM PRV Guidance


https://www.fda.gov/downloads/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/AboutMCMi/UCM592732.pdf


Last Paragraph:

"The agency (FDA) said it plans to review priority defense department products in a way that is similar to its current breakthrough designation program, which aims to speed products onto the market by relaxing certain clinical trial requirements and offering developers intensive FDA guidance.


https://www.reuters.com/article/us-johnson-johnson-zytiga/u-s-court-invalidates-jj-cancer-drug-patent-hitting-uks-btg-idUSKBN1F634X?feedType=RSS&feedName=healthNews


HC Wainwright set a $4.00 price target on Pluristem Therapeutics.